Jonas Verhoeven, Brussels (BE); Guido Alfons F. Verniest, Beerse (BE); Johannes Wilhelmus John F. Thuring, Beerse (BE); Tongfei Wu, Hever (BE); Vineet Pande, Beerse (BE); Lieven Meerpoel, Beerse (BE); Dirk Brehmer, Beerse (BE); Weimei Sun, Raritan, NJ (US); and Scott E. Denmark, Champaign, IL (US)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Filed by Janssen Pharmaceutica NV, Beerse (BE)
Filed on Jun. 10, 2021, as Appl. No. 17/344,261.
Application 17/344,261 is a continuation of application No. 16/769,793, granted, now 11,059,850, previously published as PCT/EP2018/083808, filed on Dec. 6, 2018.
Claims priority of provisional application 62/596,441, filed on Dec. 8, 2017.
Claims priority of application No. 18163867 (EP), filed on Mar. 26, 2018.
Prior Publication US 2021/0380627 A1, Dec. 9, 2021
Int. Cl. C07H 19/167 (2006.01)
CPC C07H 19/167 (2013.01)
2 Claims
1. A compound that is any one of the following:
and the pharmaceutically acceptable addition salts, and solvates thereof.